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ABSTRACT:
The Federal Food and Drug Administration (FDA) has played a critical role in the protection
of human subjects in research. Most recently, FDA enacted an interim ﬁnal rule regarding
protection of children in clinical investigations. FDA’s interim rule represents its most
current policy on human subject protection. Current events illuminate FDA’s policies and
how FDA has chosen to respond to debates over pediatric drug testing. This paper will
provide a brief history of FDA’s participation in human subject protection. This paper will
then focus on FDA’s policies for pediatric research, its interim rule, and how the interim
rule relates to current events. Finally, this paper will make a comment about how FDA
balances its competing duties of protecting the public but also of promoting research.
1I. Introduction
The Federal Food and Drug Administration (FDA) has been a critical player in the protection of human
subjects in research. Along with other governmental agencies that oversee human subject protection, FDA
has had to address various ethical issues pertaining to clinical investigations. The use of children in clinical
trials has been an area of particular sensitivity. Concerns include the inability of children to provide informed
consent and the ethical motivation not to expose children to unnecessary levels of risk in the absence of
signiﬁcant beneﬁt.1 While these ethical issues evoke a need to scrutinize pediatric research, FDA has had a
history of encouraging drug testing in children.2
Part of FDA’s motivation for encouraging drug testing in children comes from the need to ﬁnd safe and
eﬀective doses of medicine for children, to predict children’s adverse reactions to drugs, and to understand
diseases and health issues speciﬁc to kids.3 In 1963, Dr. Harry Shirkey coined the phrase “therapeutic
orphans” to describe children in the drug world.4 Few drugs have been studied on children. Pharmaceutical
companies have little ﬁnancial incentive to test drugs in kids.5 Additionally, pediatric research can be more
complicated than adult research, because tests are often done in children’s hospitals, and healthy children are
less likely to volunteer.6 Most children involved in clinical trials have the disease in question.7 The oﬀ-label
of use of medications has been the de facto standard of care in pediatrics.8 While doctors may legally use
1See Beyond Consent: Seeking Justice in Research 48 (Jeﬀrey P. Kahn, Ph.D., M.P.H. et al. eds., Oxford University
Press 1998).
2See, e.g., Paula Botstein, M.D., Why FDA is Encouraging Drug Testing in Children, FDA Consumer, July-August 1991,
available at http://www.mdadvice.com/resources/clinical trials.children.htm (including questions and answers from an
interview pertaining to drugs for children).
3See id. (stating why FDA has focused on drugs for children).
4See id. (using Dr. Shirkey’s phrase to explain why little drug testing has been performed on children).
5See id. (stating that the ﬁnancial return for testing drugs in children is likely to be small).
6Id.
7Id.
8Beyond Consent: Seeking Justice in Research 47 (Jeﬀrey P. Kahn, Ph.D., M.P.H. et al. eds., Oxford University Press
1998); see also Paula Botstein, M.D., Why FDA is Encouraging Drug Testing in Children, FDA Consumer, July-August 1991,
available at http://www.mdadvice.com/resources/clinical trials.children.htm (stating that physicians prescribe medicine
to children based on past experience and accumulated accounts of past experiences with children).
2approved drugs for whatever uses they deem appropriate, better information would facilitate more accurate
diagnoses for children.
Current events have brought pediatric research into the limelight. The Children’s Health Act of 20009
“require[d] that within 6 months of its enactment all research involving children that [was] conducted,
supported, or regulated by the Department of Health and Human Services (HHS) be in compliance with HHS
regulations providing additional protections for children involved as subjects in research.”10 The Children’s
Health Act prompted FDA to issue an interim rule containing additional safeguards for children.11 In
2001, the Kennedy Krieger Institute of Johns Hopkins University received national publicity regarding its
eﬀorts to understand the success of lead abatement programs in reducing lead exposure to children.12 Two
negligence actions pertaining to the study were brought before the Court of Appeals of Maryland.13 The
case addresses many of the ethical issues surrounding pediatric research and suggests how other courts will
interpret regulations pertaining to protection of children. In 2002, FDA asked for public comment on whether
to test smallpox vaccine on children aged two to ﬁve.14 Public and professional debate evaluating the ethical
justiﬁcations for conducting clinical trials on children emerged over the request for comment on smallpox
vaccine.15 The debate is keenly important due to recent terrorism threats and the implementation of the
ﬁrst stage of the Bush Administration’s smallpox vaccination plan.16 Lastly, on January 21, 2003, HHS
942 U.S.C. § 201 (2003).
10Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products, 66 Fed. Reg. 79,20589 (April
24, 2001) (to be codiﬁed at 21 C.F.R. pt. 50, 56). HHS protections for children are codiﬁed at 45 C.F.R. pt. 46, subpt. D.
11See Phyllis F. Granade and Mark Lutes, Recent Developments: FDA to Issue Rule Bolstering Protection of Children in
Clinical Trials, Epstein Becker & Green, P.C. (April 23, 2001), available at http://www.ebglaw.com/article 428.htm (last
visited Feb. 23, 2003).
12See Lainie Friedman Ross, In Defense of the Hopkins Lead Abatement Studies, 30 J.L. Med. & Ethics 50 (2002).
13See Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807 (2001).
14See Solicitation of Public Review and Comment On Research Protocol: A Multicenter, Randomized Dose Response Study
of the Safety, Clinical and Immune Response of Dryvax Administered to Children 2 to 5 Years of Age, 67 Fed. Reg. 211,66403
(Oct. 31, 2002).
15See Vera Sharav, Alliance for Human Research Protection, Comments re: Proposed Smallpox Vaccine Trial
to Test the Safety of Dryvax Administration to Children 2 to 5 Years of Age, FDA Docket Number 02N-0466,
available at http:www.fda.gov/ohrms/dockets/dailys/02/Dec02/120302/02N-0466-EC-450.htm (last visited Feb. 22, 2003).
16American Academy of Pediatrics, Children Should Not Be Given Smallpox Vaccine (Jan. 30, 2003), available at
http://www.aap.org/advocacy/washing/smallpox vaccine.htm (last visited Feb. 22, 2003).
3Secretary Tommy G. Thompson, responding to the Best Pharmaceuticals for Children Act,17 announced
that government-supported tests of twelve commonly prescribed drugs on children would begin in ﬁscal year
2003 and would continue to receive funding in the 2004 budget proposal.18 These events provide a telling
context in which to analyze FDA’s policies on protecting children in clinical investigations and illuminate
FDA’s response to debates over pediatric research.
To set the stage for analysis, this paper will ﬁrst provide a background of human subject regulation and an
overview of the historic eﬀorts of FDA to protect research subjects.
II. History of Human Subject Regulation
A.
Overview of Human Subject Protections
Research regulation began during the Nuremberg War Crime Trials following World War II.19 The trials
produced the Nuremberg Code, which outlines “fundamental ethical principles in human subject research.”20
The code was “the ﬁrst internationally recognized set of guidelines in human subject research” and is now
part of international common law.21 The code contains ten basic guidelines that emphasize voluntary consent
and avoidance of unnecessary risk.22 Courts in the United States, however, have not used the Nuremberg
Code in any criminal case and rarely cite to the code in the civil context.23 Despite its limited use, the
17Pub. L. No. 107-109, 115 Stat. 1408 (2002).
18Department of Health and Human Services, HHS Identifies Drugs for Pediatric Testing and Announces FY
2003 and FY 2004 Funding (2003), available at http://www.hhs.gov/news/press/2003pres/20030121.html (last visited Feb.
22, 2003).
19See Module 1: Research Ethics, available at http://research.bcm.tmc.edu/CR%20Tutorial/1research ethics.htm (last
visited Feb. 22, 2003) (providing a historical perspective on research ethics).
20Id.
21Id.
22See Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 835 (2001) (listing the complete text of the Nuremberg Code).
23See id.
4Nuremberg Code has served as a model for subsequent ethical standards.24
The most inﬂuential post-Nuremberg documents have been the Declaration of Helsinki (“The Declaration”),
ﬁrst issued in 1964 and last revised in 1996, and the Belmont Report of 1979.25 The Declaration of Helsinki,
adopted by the World Medical Association (WMA) in response to the testing of new polio vaccines on institu-
tionalized mentally retarded children,26 added to the recommendations found in the Nuremberg Code.27 For
example, the declaration distinguishes therapeutic from non-therapeutic research,28 suggests that research
on humans be justiﬁed by prior laboratory and animal experimentation, aﬃrms the need to compare the
importance of a study in proportion to its risk, and provides the framework for what has become independent
Institutional Review Boards (IRBs).29
In 1979, the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Re-
search issued the Belmont Report.30 The Belmont Report contains three basic ethical principles, including
respect for persons, beneﬁcence, and justice.31 Respect for persons refers to respect for individual autonomy
24See Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (National
Commission 1979).
25Module 1: Research Ethics, available at http://research.bcm.tmc.edu/CR%20Tutorial/1research ethics.htm (last visited
Feb. 22, 2003).
26See Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 836 (2001).
27See Module 1: Research Ethics, available at http://research.bcm.tmc.edu/CR%20Tutorial/1research ethics.htm (last
visited Feb. 22, 2003).
28Therapeutic research involves studies designed to help or aid an individual who is suﬀering from a disease or health condition.
Nontherapetuic research involves individuals who are not known to have the health condition addressed by the study or who
will not directly beneﬁt from the research; nontherapetuic research is “designed to achieve beneﬁcial results for the public at
large (or, under some circumstances, for proﬁt).” Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 812 n.2 (2001).
29See id. IRBs evaluate research studies in order to ensure the safety of human subjects. All federally funded research must
obtain IRB approval. See 45 C.F.R. § § 46.107-115 (2002) (outlining requirements for makeup and operation of IRBs); see also
Oﬃce of Inspector General, Institutional Review Boards: A Time for Reform 3 (Jun. 1998) (including an overview of basic
IRB functions).
30See Module 1: Research Ethics, available at http://research.bcm.tmc.edu/CR%20Tutorial/1research ethics.htm (last
visited Feb. 22, 2003).
31See Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (National
Commission 1979).
5and protection for those with diminished autonomy.32 The principle now appears embodied in requirements
of informed consent.33 Beneﬁcence entails an obligation not to harm and to maximize possible beneﬁts and
minimize possible harm.34 Beneﬁcence has become apparent in the risk/beneﬁt calculus.35 Finally, justice
includes the idea that people with entitled beneﬁts should receive them and that no one should face undue
burdens.36 This concept of justice appears in moral requirements of equitable procedures and outcomes in
subject recruitment.37 The recommendations from The Declaration of Helsinki and The Belmont Report
have been codiﬁed in 45 CFR § 46, which is known as the Common Rule.38 Seventeen government agencies
have endorsed the Common Rule.39 The Common Rule serves as the codiﬁed federal policy for protection
of human subjects.40
In 1996, the International Conference on Harmonization (ICH) added to and modiﬁed the federal regula-
tions.41 Collectively, the Common Rule and the recommendations make up what is known as Good Clinical
Practice or GCP.42 On June 13, 2000, HHS created the Oﬃce of Human Research Protections (“OHRP”).43
OHRP has responsibility for developing, monitoring and exercising compliance oversight for regulations and
32See id.
33See Module 1: Research Ethics, available at http://research.bcm.tmc.edu/CR%20Tutorial/1research ethics.htm (last
visited Feb. 22, 2003).
34See Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (National
Commission 1979).
35See Module 1: Research Ethics, available at http://research.bcm.tmc.edu/CR%20Tutorial/1research ethics.htm (last
visited Feb. 22, 2003).
36See Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (National
Commission 1979).
37See Module 1: Research Ethics, available at http://research.bcm.tmc.edu/CR%20Tutorial/1research ethics.htm (last
visited Feb. 22, 2003).
38See id.
39The agencies endorsing the Common Rule include the Department of Agriculture, Department of Energy, National Aero-
nautic and Space Administration, Department of Commerce, Consumer Product Safety Commission, Agency for International
Development, Department of Housing and Urban Development, Department of Justice, Department of Defense, Department
of Education, Department of Veteran Aﬀairs, Environmental Protection Agency, Department of Health & Human Services,
National Science Foundation, Department of Energy, Central Intelligence Agency, and the Social Security Administration.
See Terms of the Federalwide Insurance, available at http://ohrp.osophs.dhhs.gov/humansubjects/assurance/filasurt.htm
(last visited Feb. 18, 2003).
40See 45 C.F.R. § 46 (2002). The Common Rule requires written assurances of a commitment to human subject protection
from institutions engaged in research and existence of an IRB and compliance with IRB requirements. See id.
41See Module 1: Research Ethics, available at http://research.bcm.tmc.edu/CR%20Tutorial/1research ethics.htm (last
visited Feb. 22, 2003).
42See id.
4365 Fed. Reg. 114,37136 (June 13, 2000).
6for research conducted by all HHS component agencies.44 While FDA, as part of HHS, attempts to remain
consistent with the Common Rule, its regulatory structure is unique.
B.
Overview of FDA Regulations
FDA’s regulatory structure is distinctive, because in addition to attempting to remain consistent with the
Common Rule, FDA must also consider the requirements of the Federal Food, Drug, and Cosmetic Act.45
Moreover, the fact that FDA seldom supports or conducts research of its own also contributes to its unique
framework.46 FDA regulations apply to IRBs that review clinical investigations regulated by FDA and that
support applications for research or marketing permits for products regulated by FDA.47 Included in this
category are experiments that must meet the requirements for prior submission to FDA and experiments
intended for later submission to or inspection by FDA as part of an application for a research or a marketing
permit.48 All individuals, including healthy patients, who participate in research as recipients of a test article
or as controls, receive FDA’s protections.49
Various sets of FDA regulations apply to clinical practice and clinical trials. Among the regulations are stan-
dards for investigational new drug applications,50 standards for applications for FDA approval to market
44See id.
4556 Fed. Reg. 280003 (Jun. 18, 1991). The Federal, Food, Drug, and Cosmetic Act of 1938, revised by the FDA
Modernization Act of 1997, establishes the basic legal framework controlling the activities of producers of food, drugs, cosmetics,
and medical devices. Key components of the act include deﬁnitions and regulations pertaining to adulteration and misbranding.
An example of how the FDCA may aﬀect human subject protection appears in Section 528, which includes special instructions
for investigations of drugs for rare diseases and conditions.
46Instead of conducting or supporting research of its own, “FDA regulates research conducted by outside sponsors and
investigators, where the research is subject to IRB review and approval.” Additional Safeguards for Children in Clinical
Investigations of FDA-Regulated Products, 66 Fed. Reg. 79,20591 (April 24, 2001) (to be codiﬁed at 21 C.F.R. pt. 50, 56).
47See 21 C.F.R. § 56.101 (2002).
48See 21 C.F.R. § 56.102 (2002).
49See id.
50See 21 C.F.R. pt. 312 (2002).
7new drugs and approval for biologic licenses,51 standards pertaining to investigational device exemptions,52
and standards regarding premarket approval of medical devices.53 Similar to other departments, FDA re-
quires that researchers conform to GCP standards.54 To ensure compliance, FDA “inspects and audits the
conduct and reporting of clinical trials.”55 Inspections are in addition to internal review of new product
applications and cover all involved parties, including clinical investigators, IRBs, sponsors, monitors, and
contract research organizations.”56
Certain sets of FDA regulations refer speciﬁcally to human subject protection, including rules regarding
electronic signatures,57 informed consent,58 ﬁnancial disclosure by clinical investigators,59 and IRB require-
ments.60 While these regulations have been harmonized with the Common Rule,61 diﬀerences still exist.62
Unlike the Common Rule, FDA regulations do not require assurances.63 In their place, FDA utilizes its
Biosearch Monitoring program and educational eﬀorts to assure compliance with FDA regulations.64 Simi-
lar to the Common Rule, FDA requires continuing review by IRBs but exempts certain investigations, such
as trials commencing prior to July 7, 1981 and emergency uses of test articles.65 Other disparities from
the Common Rule pertain to how FDA may respond to noncompliance situations and the requirements for
informed consent.66
51See 21 C.F.R. pt. 314, 601 (2002).
52See 21 C.F.R. pt. 812 (2002).
53See 21 C.F.R. pt. 814 (2002).
54See U.S. Food and Drug Administration, Good Clinical Practice in FDA-Regulated Clinical Trials, available at
http://www.fda.gov/oc/gcp/default.htm (last visited Feb. 23, 2003).
55Id. The program is known as the Biosearch Monitoring (BIMO) program. Id.
56Id.
57See 21 C.F.R. pt. 11 (2002).
58See 21 C.F.R. pt. 50 (2002).
59See 21 C.F.R. pt. 54 (2002).
60See 21 C.F.R. pt. 56 (2002).
61The regulations were harmonized in 1991. See Comparison of DA and HHS Human Subject Protection, available at
http://www.fda.gov/oc/gcp/comparison.html (last visited Feb. 28, 2003).
62See id. (stating that diﬀerences in the rules are due to diﬀerences in the statutory scope or requirements).
63See id. FDA believes that adopting the assurance mechanism would create too large of an administrative burden to justify
the beneﬁts that would come from assurance of IRBs that are subject to FDA jurisdiction but not otherwise subject to HHS
jurisdiction. See id.
64See id.
65See id.; see also 21 C.F.R. § 56.104 (2002).
66See id. For example, FDA regulations exempt certain life threatening and emergency situations from informed consent.
8III. FDA Regulations Pertaining Speciﬁcally to Children in Clinical Trials
FDA’s issuance of its interim ﬁnal rule, Additional Safeguards for Children in Clinical Investigations of
FDA-Regulated Products,67 adopted in response to the Children’s Health Act, represents its most success-
ful eﬀort at codifying regulations pertaining speciﬁcally to children in clinical investigations. Prior to the
Children’s Health Act, if an FDA-regulated clinical investigation was not conducted or supported by HHS,
HHS regulations on protection of children did not impose requirements on the investigation.68 Historically,
however, FDA turned to HHS regulations for guidance on pediatric studies.69 Much of the interim rule is
based on the HHS regulations, “with only those changes necessary due to diﬀerences between FDA’s and
HHS’s regulatory authority.”70 Research involving FDA-regulated products that is also conducted or sup-
ported by HHS must satisfy both sets of regulations.71
Prior to the interim rule, in addition to relying upon guidance from HHS regulations, FDA had some safe-
guards in place for pediatric research.72 21 C.F.R. § 56, which pertains to governance of IRBs, identiﬁes
children as a class of vulnerable subjects, and portions of § 56 address pediatric issues.73 For example,
Section 56.111(a)(3) requires that selection of research subjects be “cognizant of the special problems of
research involving vulnerable populations, such as children.”74 Section 56.111(b) requires special attention
to the rights and welfare of children, because they are vulnerable to coercion or undue inﬂuence.75 Section
56.107(a) provides for consideration of including one or more individuals who are knowledgeable about and
See 21 C.F.R. § 50.23(a)-(c) (2002). FDA regulations also contain a waiver of informed consent for military personnel, which
has no comparable provision in the Common Rule. See 21 C.F.R. § 50.23(d) (2002).
6721 CFR pt. 50, subpt. D (2002).
68Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products, 66 Fed. Reg. 79,20590 (April
24, 2001) (to be codiﬁed at 21 C.F.R. pt. 50, 56). HHS regulations are codiﬁed at 45 C.F.R. part 46, subpart d.
69See id.
70Id.
71See id.
72Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products, 66 Fed. Reg. 79,20590 (April
24, 2001) (to be codiﬁed at 21 C.F.R. pt. 50, 56).
73Id.
74Id. (citing 21 C.F.R. § 56.111(a)(3)).
75Id.
9experienced in working with children to sit on an IRB that regularly reviews research that involves chil-
dren.76 Other safeguards were FDA publications regarding informed consent and the assent of children.77
Lastly, FDA published guidance entitled E11 Clinical Investigation of Medicinal Products in the Pediatric
Population (ICH E11), which addressed issues in pediatric drug development including ethical considerations
in pediatric studies.78
FDA designed the interim rule with hopes of helping researchers address ethical issues that were to accom-
pany an expected increase in the enrollment of children in clinical trials.79 FDA expected increases in the
number of children participating in clinical investigations due to, then recent, pediatric initiatives, including
FDA’s 1998 pediatric rule and the pediatric provisions of the Food and Drug Administration Modernization
Act of 1997.80 The interim rule became eﬀective on April 30, 2001.
The interim rule is divided into seven parts, all codiﬁed at 21 C.F.R. Part 50, subpart D. Much of the rule
focuses on duties of IRBs. Part 50.50 requires IRBs to review clinical investigations involving children as
subjects and to approve only those investigations that satisfy the criteria described in Section 50.51, Section
50.52, or Section 50.53 and the conditions of all other applicable sections of” subpart D.81
76Id.
77See id. (referring to the information sheets, which state that HHS regulations may be used as guidance for all pediatric
studies).
78Id. at 20590-91.
79Phyllis F. Granade and Mark Lutes, Recent Developments: FDA to Issue Rule Bolstering Protection of Children in Clinical
Trials, Epstein Becker & Green, P.C. (April 23, 2001), available at http://www.ebglaw.com/article 428.htm (last visited Feb.
23, 2003).
80See Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products, 66 Fed. Reg. 79 20589 (April
24, 2001) (to be codiﬁed at 21 C.F.R. pt. 50, 56).
The 1998 pediatric rule (63 Fed. Reg. 231,66632 (Dec. 2, 1998)) requires manufacturers to “assess the safety and eﬀectiveness
of certain drug and biological products in pediatric patients” and authorizes FDA to require pediatric studies of marketed drug
and biological products that: “(1) Are used in a substantial number of pediatric patients for the labeled indications, and where
the absence of adequate labeling could pose signiﬁcant risks to pediatric patients; or (2) would provide a meaningful therapeutic
beneﬁt over existing treatments for pediatric patients for one or more of the claimed indications, and the absence of adequate
labeling could pose signiﬁcant risks to pediatric patients.” Id.
The Modernization Act (Public Law 105-115) “establishe[s] economic incentives for manufactures to conduct pediatric studies
on drugs for which exclusivity or patent protection is available under the Drug Price Competition and Patent Restoration Act
(Public Law 98-417) or the Orphan Drug Act (Public Law 97-414).” Id. FDA has also published several pediatric guidance
documents, which also could have contributed to increased numbers of pediatric studies for FDA-regulated products. Id. at
20590.
8121 C.F.R. § 50.50 (2002) (IRB duties).
10Section 50.51 requires that in clinical trials in which no greater than minimal risk to children is present, the
IRB must ﬁnd and document adequate provisions “soliciting the assent of the children and the permission
of their parents or guardians as set forth in Sec. 50.55.”82 Thus, so long as there is only minimal risk, and
so long as proper consent is obtained, FDA permits the use of children as research subjects.
In its notice to the public announcing its intent to establish an interim rule, FDA recognized that the level
of risk in a study might change during the course of a clinical investigation.83 FDA, however, noted that
measures, such as “exit strategies in the case of adverse events or a lack of eﬃcacy,” or establishment of a
data monitoring committee (DMC) to review ongoing data collection might help mitigate unexpected risk.84
Section 50.52 allows clinical investigations with more than minimal risk to children to take place if the risk
is “presented by an intervention or procedure that holds out the prospect of direct beneﬁt for the individual
subject, or by a monitoring procedure that is likely to contribute to the subject’s well-being.”85 Thus, re-
search for therapeutic beneﬁt may take place even with enhanced risk. For the investigation to be allowed,
however, the IRB must ﬁnd and document that:
(a)
The risk is justiﬁed by the anticipated beneﬁt to the subjects;
(b) The relation of the anticipated beneﬁt to the risk is at least as favorable to the subjects as that pre-
sented by available alternative approaches; and
(c) Adequate provisions are made for soliciting the assent of the children and permission of their parents
or guardians as set froth in Sec. 50.55.86
8221 C.F.R. § 50.51 (2002) (Clinical investigations not involving greater than minimal risk).
83See Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products, 66 Fed. Reg. 79,20593 (April
24, 2001) (to be codiﬁed at 21 C.F.R. pt. 50, 56).
84Id.
8521 C.F.R. § 50.52 (2002) (Clinical investigations involving greater than minimal risk but presenting the prospect of direct
beneﬁt to individual subjects).
86Id.
11If an intervention or procedure poses more than minimal risk to children in a clinical investigation and the
risk “does not hold out the prospect of direct beneﬁt for the individual subject,” or if a monitoring procedure
“is not likely to contribute to the well-being of the subject,” then Section 50.53 applies.87 Section 50.53
allows trials of this nature to take place, provided that the IRB ﬁnds and documents that:
(a)
The risk represents a minor increase over minimal risk;
(b) The intervention or procedure presents experiences to subjects that are reasonably commensurate with
those inherent in their actual or expected medical, dental, psychological, social, or educational situations;
(c) The intervention or procedure is likely to yield generaliazable knowledge about the subjects’ disorder
or condition that is of vital importance for the understanding or amelioration of the subjects’ disorder or
condition; and
(d) Adequate provisions are made for soliciting the assent of the children and permission of their parents
or guardians as set forth in Sec. 50.55.88
Thus, even in cases lacking direct beneﬁt to the subjects, minor increases in risk that replicate
normal amounts of risk in a child’s everyday life, may be justiﬁed by beneﬁts of generalizable
knowledge. The knowledge gained, however, must contribute to bettering or understanding the
speciﬁc subject’s condition; therefore, whether nontherapeutic research is permissible under Section
50.53 remains open to interpretation.
Remaining consistent with its desire to encourage drug testing in children, FDA allows even questionable
trials that do not meet the requirements of Section 50.51, Section 50.52, or Section 50.53 to take place if the
8721 C.F.R. § 50.53 (2002) (Clinical investigations involving greater than minimal risk and no prospect of direct beneﬁt to
individual subjects, but likely to yield generalizable knowledge about the subjects’ disorder or condition).
88Id.
12requirements of Section 50.54 are met. Section 50.54 allows investigations to proceed provided that:
(a)
The IRB ﬁnds and documents that the clinical investigation presents a
reasonable opportunity to further the understanding, prevention, or alleviation of a
serious problem aﬀecting the health or welfare of children; and
(b) The Commissioner of Food and Drugs, after consultation with a panel of experts in pertinent disci-
plines (for example: science, medicine, education, ethics, law) and following opportunity for public review
and comment, determines either:
(1)
That the clinical investigation in fact satisﬁes the condi-
tions of Sec. 50.51, Sec. 50.52, or Sec. 50.53, as applicable, or
(2) That the following conditions are met:
(i)
The clinical investigation presents a reasonable
opportunity to further the understanding, prevention, or alleviation of a
serious problem aﬀecting the health or welfare of children;
(ii) The clinical investigation will be conducted in accordance with sound ethical principles; and
(iii) Adequate provisions are made for soliciting the assent of children and the permission of their parents
or guardians as set forth in Sec. 50.55.89
Section 50.54 clearly leaves room open to allow for nontherapeutic studies. To alleviate ethical concerns,
FDA makes the approval process burdensome and calls for consultation with experts and public comment
8921 C.F.R. § 50.54 (2002) (Clinical investigations not otherwise approvable that present an opportunity to understand,
prevent, or alleviate a serious problem aﬀecting the health or welfare of children).
13to hold FDA accountable.
In any clinical investigation, no matter how much risk is present, FDA has required that proper procedures
be followed to obtain adequate consent. Section 50.55 outlines the requirements for soliciting the assent
of children and the permission of their parents or guardians.90 The requirements are in addition to the
“determinations required under other applicable sections of [] subpart D.”91
Section 50.55 requires the IRB to “determine that adequate provisions are made for soliciting the assent
of the children when in the judgment of the IRB the children are capable of providing assent.”92 Thus,
FDA places importance in obtaining the actual child’s consent where feasible. To determine whether a child
is capable of providing assent, the IRB must take into account the age, maturity, and psychological state
of the child.93 The IRB may make this judgment “for all children to be involved in clinical investigations
under a particular protocol, or for each child, as the IRB deems appropriate.”94 The assent of children in
an investigation is not a necessary condition for proceeding with the investigation if the IRB ﬁnds:
(1)
That the capability of some or all of the children is so limited that they
cannot reasonably be consulted, or
(2) That the intervention or procedure involved in the clinical investigation holds out a prospect of direct
beneﬁt that is important to the health or well-being of the children and is available only in the context of
the clinical investigation.95
90See 21 C.F.R. § 50.55 (2002) (Requirements for permission by parents or guardians and for assent by children).
9121 C.F.R. § 50.55(a) (2002).
92Id.
9321 C.F.R. § 50.55(b) (2002).
94Id.
9521 C.F.R. § 50.55(c) (2002).
14Section 50.55 further provides that even where the IRB determines that the children are capable of assenting,
the IRB may waive the assent requirement if it ﬁnds and documents that:
(1)
The clinical investigation involves no more than minimal risk to the
subjects;
(2) The waiver will not adversely aﬀect the rights and welfare of the subjects;
(3) The clinical investigation could not practicably be carried out without the waiver; and
(4) Whenever appropriate, the subjects will be provided with additional pertinent information after par-
ticipation.96
In addition to all other requirements under applicable sections of subpart D, “the IRB must determine that
the permission of each child’s parent or guardian is granted.”97 Where clinical investigations are covered
by Section 50.51 or Section 50.52, “the IRB may ﬁnd that the permission of one parent is suﬃcient, if
consistent with State law.”98 For trials covered by Section 50.53 or Section 50.54, “both parents must
give their permission unless one parent is deceased, unknown, incompetent, or not reasonably available, or
when only one parent has legal responsibility for the care and custody of the child if consistent with State
law.”99 Thus, nontherapeutic research, if allowed, may only take place where both parents consent to the
investigation.
In all situations requiring parental consent, “permission by parents or guardians must be documented in
9621 C.F.R. § 50.55(d) (2002).
9721 C.F.R. § 50.55(e) (2002).
98Id.
99Id.
15accordance with and to the extent required by Sec. 50.27.”100 Moreover, the IRB “must also determine
whether and how much assent must be documented.”101
The ﬁnal additional safeguard found in the interim rule pertains to children who are wards of the State or
wards of any other agency, institution, or entity.102 Section 50.56 allows these children to be included in
clinical investigations only if such investigations are:
(1)
Related to their status as wards; or
(2) Conducted in schools, camps, hospitals, institutions, or similar settings in which the majority of
children involved as subjects are not wards.103
10021 C.F.R. § 50.55(f) (2002).
10121 C.F.R. § 50.55(g) (2002).
102See 21 C.F.R. § 50.56 (2002) (Wards). These requirements prohibit investigators from using children who are wards merely
because of convenience. See Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products, 66 Fed.
Reg. 79,20595 (April 24, 2001) (to be codiﬁed at 21 C.F.R. pt. 50, 56).
10321 C.F.R. § 50.56(a) (2002).
16Investigations meeting these requirements must mandate appointment of an advocate for each child
who is a ward.”104 The advocate “will serve in addition to any other individual acting on behalf of
the child as guardian or in loco parentis.”105 An advocate may represent more than one child.106 To
qualify, the advocate must have “the background and experience to act in, and agree to act in, the
best interest of the child for the duration of the child’s participation in the clinical investigation.”107
Finally, “[t]he advocate must not be associated in any way (except in the role as advocate or member
of the IRB) with the clinical investigation, the investigator(s), or the guardian organization.108 This
safeguard resembles protections pertaining to ﬁnancial disclosure and eﬀorts to avoid conﬂicts of
interest.
In summary, the interim rule seems consistent with FDA’s policy of encouraging drug testing in children. At
the same time, the rule seems to represent good faith eﬀorts to recognize ethical dilemmas and to provide
adequate safeguards for children. Looking at how provisions of the rule relate to issues raised in current
events may illuminate FDA’s response to pediatric research.
IV. Application of Interim Rule to Recent Events
A.
John Hopkins Lead Abatement
Study
Although not directly related to FDA, the Maryland court case addressing the Kennedy Krieger Institute’s
17(KKI) lead abatement study raises many of the issues inherent in debates about pediatric research. 109 The
purpose of KKI’s study was to determine how eﬀective varying degrees of lead paint abatement procedures
were in reducing levels of lead in housing.110 After arranging for various degrees of lead abatement mod-
iﬁcation to be performed in certain homes, KKI encouraged landlords to rent the homes to families with
young children.111 The researchers anticipated that children living in the homes “would, or at least might,
accumulate lead in their blood from the dust,” thus enabling them to measure the success of various abate-
ment procedures.112 Although nontherapeutic in nature,113 arguably, the research protocol was justiﬁed
by anticipated future beneﬁts that would result from knowing which abatement procedures were eﬀective.
This knowledge would help children at large, especially due to the fact that deteriorating lead paint in older
housing is the number one source of lead exposure in children in the United States.114
The Court of Appeals for Maryland found the nontherapeutic nature of the program to be problematic.115
The court stated, “In our view, otherwise healthy children should not be the subject of nontherapetuic
experimentation or research that has the potential to be harmful to the child.”116 Later in the opinion, the
court held that “in Maryland a parent, appropriate relative, or other applicable surrogate, cannot consent
to the participation of a child... in nontherapetuic research or studies in which there is any risk of injury or
109While the case does not speciﬁcally concern FDA regulations, it does address HHS regulations and portions of the Common
Rule. See Grimes v. Kennedy Krieger, Inst., Inc., 782 A.2d 807, 846-49 (2001).
110See id. at 812.
111See id. at 811-12. In one of the cases at bar, the Institute arranged for the landlord to receive public funding to aid in the
modiﬁcations. See id.
112Id. at 813.
113But see id. at 817 (explaining that the IRB reviewing the study encouraged the researchers to misrepresent the purpose of
the study in order to bring it under the label of “therapeutic”).
114See Dixie Farley, U.S. Food and Drug Administration, Dangers of Lead Still Linger, FDA Consumer (Jan.-Feb.
1998), available at http://www.cfsan.fda.gov/∼dms/fdalead.html (last visited Feb. 22, 2003) (discussing dangers of lead
paint).
115See Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 814-15 (2001) (declaring that otherwise healthy children should
not be enticed into a situation in which they accumulate lead in their blood; also ﬁnding that the study should not have been
presented in the nonetherapeutic context in the ﬁrst place).
116Id. at 850.
18damage to the health of the subject.”117
In addition to the nontherapetuic nature of the study, other issues rendered the research problematic. Most
of the families involved in the study were of lower economic status.118 Arguably, KKI inﬂuenced these
families to participate by promising, in the consent form, to pay them periodic sums and by providing
ongoing incentives, such as coupons for food and gifts for the children.119 Subject recruitment has been an
evolving concern in human subject protection.
Much of the case focused on whether the researchers owed a duty of care to the parents and their children.
Assuming there was a duty, plaintiﬀs argued that KKI was negligent in failing to completely and accurately
inform the parents of the risk involved in the study and in failing to provide proper information about test
results during the study. The consent agreements did not fully explain the design of the study.120 Parents
did not completely understand that their children “might, and perhaps were anticipated to, accumulate
some level of lead contaminations in their blood, and that the lead content of the children’s blood would
be one of the methods” by which KKI would measure the success of the abatement programs.121 Moreover,
in one of the cases before the court, KKI neglected to timely inform a child’s mother that dust testing in
her home revealed higher levels of lead than what might be found in a completed abated house.122 KKI
disclosed the information nine months later, after the child’s blood was found to contain elevated levels of
blood.123 Failing to disclose this information could have resulted in adverse health consequences. By the
time symptoms of lead poisoning appear in children, damage is often irreversible.124 Moreover, symptoms
117Id. at 858.
118See id. at 813.
119See id. at 843 n.4.
120See id. at 813.
121Id. at 828. But see Lainie Friedman Ross, In Defense of the Hopkins Lead Abatement Studies, 30 J.L. Med. & Ethics
50 (2002) (arguing that “the consent forms clearly explained that living in housing that had undergone renovation for lead
abatement may not fully protect one’s child from lead exposure.”).
122See Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 825 (2001).
123Id.
124See Dixie Farley, U.S. Food and Drug Administration, Dangers of Lead Still Linger, FDA Consumer (Jan.-Feb.
1998), available at http://www.cfsan.fda.gov/∼dms/fdalead.html (last visited Feb. 22, 2003) (discussing dangers of lead
poisoning).
19of lead poisoning “can be highly variable depending, in part, on the age of the child, the amount of lead to
which the child is exposed, and how long the exposure goes on.”125 Without disclosure by KKI, the mother
would have been unable to take preventive measures to help her child. The court overruled the lower court’s
summary judgment ruling on the negligence issues and found that a special relationship could exist between
a researcher and its research subjects.
Whether the ﬁndings in this case will aﬀect FDA is unclear. Amici to the case pointed out that some of
the court’s rulings are inconsistent with the federal regulations pertaining to participation of children in
research.126 For example, similar to the provisions in FDA’s interim rule, the federal regulations permit
children to participate in nontherapetuic research posing only minimal risk or posing more than minimal
risk if certain conditions are present.127 The Maryland court’s holding seems to suggest that studies with
any risk are not appropriate if nontherapeutic in nature. Later, however, the court, denying the motion for
reconsideration, clariﬁed its decision.128 The court stated that whether nontherapeutic research is lawful
depends upon the amount of risk inherent in a study and its expected beneﬁt.129 The court clariﬁed that
these issues were left open for further factual development on remand.130 Thus, the case can be reconciled
with the federal regulations and any challenges based upon the court’s holdings probably would not aﬀect
FDA’s regulations on their face. Room for argument, however, exists over whether it is ethical to expose
healthy children to nontherapeutic research; these issues may be important if a future case occurred. While
125Id. (quoting pediatrician Randolph Wykoﬀ, M.D., FDA associate commissioner for operations) (internal quotations omit-
ted).
126See Lainie Friedman Ross, In Defense of the Hopkins Lead Abatement Studies, 30 J.L. Med. & Ethics 50 (2002).
127See id. (citing 45 C.F.R. §§ 46.404, 46.406, 46.407, 45.408 (1991)). For example, 45 C.F.R. § 46.404 allows nontherapeutic
research that poses more than minimal risk to take place if the research has potential to oﬀer generalizable knowledge of vital
importance about the subjects’ disorder or condition. See id. (citing 45 C.F.R. § 46.404). Additionally, 45 C.F.R. § 46.407
allows nontherapetuic research posing more than a minor increase over minimal risk to take place if the research will help
alleviate serious health problems and a national panel of experts approves the research. See id. (citing 45 C.F.R. § 46.407).
128See id. (citing Grimes v. Kennedy Krieger, Inst., Inc., No. 128 (Md. Oct. 11, 2001) (order denying motion for
reconsideration) at 1, available at http://www.hopkinsmedicine.org/press/2001/October/CourtofAppeals.pdf).
129See id. (citing Grimes v. Kennedy Krieger, Inst., Inc., No. 128 (Md. Oct. 11, 2001) (order denying motion for
reconsideration) at 2, available at http://www.hopkinsmedicine.org/press/2001/October/CourtofAppeals.pdf).
130See id. (citing Grimes v. Kennedy Krieger, Inst., Inc., No. 128 (Md. Oct. 11, 2001) (order denying motion for
reconsideration) at 2, available at http://www.hopkinsmedicine.org/press/2001/October/CourtofAppeals.pdf).
20the value of the court’s holdings as precedent is unclear, the case does aﬃrm a right of human subjects to
go to court to seek redress for any wrongs committed in a research study.131 If future litigation becomes
prevalent, FDA’s regulations could be challenged.
B. Children’s Smallpox Vaccine Trial
Another current event that relates to FDA’s policies for protection of children involves the smallpox vaccine.
The vaccine has brought FDA’s policies under public scrutiny. On October 31, 2002, FDA placed a notice in
the Federal Register to seek public opinion on whether FDA should proceed with a trial to vaccinate young
children with smallpox vaccine.132 While it is highly unusual for FDA to seek public opinion on research,133
21 C.F.R. § 50.54 requires that public comment be sought where it is unclear whether the proposed research
meets the requirements of Section 50.1, Section 50.2, or Section 50.3. In this case, the IRB “was unable to
assess the prospect of direct beneﬁt” to the children “but found that the research presented a reasonable op-
portunity to further the understanding, prevention or alleviation of a serious problem aﬀecting the health or
welfare of the children.”134 These facts made Section 50.54 relevant. Additionally, the climate of the country
and the fact that “[s]mallpox vaccine is the most highly reactive vaccine that has ever been routinely used
in humans” probably motivated the FDA to go public.135 Hundreds of people voiced opinions in response
to the notice.136
131See Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 851 (2001) (stating that the rights of human subjects “are
aﬀorded the protection of the courts when such subjects seek redress for any wrongs committed”).
132See Susan J. Landers, Prudent to Test Smallpox Vaccine in Kids?, American Medical News (Dec. 2, 2002), available at
http://www.ama-assn.org/sci-pubs/amnews/pick 02/hlsc1202.htm (last visited Feb. 28, 2002).
133See FoxNews.com, FDA Mulls When Smallpox Vaccine Study Should Begin for Children (Nov. 1, 2002), at
http://www.foxnews.com/story/0,2933,68722,00.html.
134Solicitation of Public Review and Comment On Research Protocol: A Multicenter, Randomized Dose Response Study of
the Safety, Clinical and Immune Response of Dryvax Administered to Children 2 to 5 Years of Age, 67 Fed. Reg. 66404 (Oct.
31, 2002).
135See Vera Sharav, Alliance for Human Research Protection, Comments re: Proposed Smallpox Vaccine Trial
to Test the Safety of Dryvax Administration to Children 2 to 5 Years of Age, FDA Docket Number 02N-0466, at 1,
available at http:www.fda.gov/ohrms/dockets/dailys/02/Dec02/120302/02N-0466-EC-450.htm (last visited Feb. 22, 2003).
136See Susan J. Landers, American Medical News, Prudent to Test Smallpox Vaccine in Kids? (Dec. 2, 2002), available at
http://www.ama-assn.org/sci-pubs/amnews/pick 02/hlsc1202.htm (last visited Feb. 28, 2002).
21The proposed trial would involve inoculating forty children, aged two to ﬁve, with the vaccine, called Dry-
vax.137 Dryvax was pulled out of storage after being frozen for approximately thirty years.138 The govern-
ment terminated routine vaccination against smallpox in 1971, partly because of the severe side eﬀects of
the disease and partly because of the low risk of exposure to smallpox.139 In 2001, the Center for Disease
and Control (CDC) began inoculating members of its staﬀ with Dryvax to prepare for a possible outbreak
of smallpox due to terrorist threats.140 CDC, however, allegedly stopped vaccinating, because the adverse
reactions were greater than anticipated.141 Currently, as prompted by the Bush Administration, smallpox
vaccines are being administered to public health oﬃcials to prepare for a possible biological attack.142
Much of the criticism of the smallpox trial has focused on the risk/beneﬁt calculus. Based on data from
the 1960s, “CDC estimates that for every 1 million people vaccinated for the ﬁrst time about 1,000” will
experience serious reactions.143 In 14 to 52 of those cases, the eﬀects may be life threatening.144 More-
over, children less than ﬁve years of age are at greater risk of developing adverse side eﬀects than other
age groups.145 Also involved in the risk factor is the possibility of exposure to third parties. In the past,
fatalities occurred in close household contacts of recently vaccinated family members.146 To minimize third
party exposure, researchers plan to take vaccinated children out of day care and school.147 Researchers have
137See FoxNews.com, FDA Mulls When Smallpox Vaccine Study Should Begin for Children (Nov. 1, 2002), at
http://www.foxnews.com/story/0,2933,68722,00.html.
138See Vera Sharav, Alliance for Human Research Protection, Comments re: Proposed Smallpox Vaccine Trial
to Test the Safety of Dryvax Administration to Children 2 to 5 Years of Age, FDA Docket Number 02N-0466, at 3,
available at http:www.fda.gov/ohrms/dockets/dailys/02/Dec02/120302/02N-0466-EC-450.htm (last visited Feb. 22, 2003).
139See id. at 1.
140See id. at 3.
141See id.
142See FoxNews.com, FDA Mulls When Smallpox Vaccine Study Should Begin for Children (Nov. 1, 2002), at
http://www.foxnews.com/story/0,2933,68722,00.html; see also Declaration Regarding Administration of Smallpox Coun-
termeasures, 68 Fed. Reg. 18,4212 (Jan. 28, 2003).
143Vera Sharav, Alliance for Human Research Protection, Comments re: Proposed Smallpox Vaccine Trial to
Test the Safety of Dryvax Administration to Children 2 to 5 Years of Age, FDA Docket Number 02N-0466, at 1,
available at http:www.fda.gov/ohrms/dockets/dailys/02/Dec02/120302/02N-0466-EC-450.htm (last visited Feb. 22, 2003).
144See id.
145See id.
146See id. at 2.
147See FoxNews.com, FDA Mulls When Smallpox Vaccine Study Should Begin for Children (Nov. 1, 2002), at
http://www.foxnews.com/story/0,2933,68722,00.html.
22also implemented a response plan that will treat possible severe reactions with vaccinia immune globulin
and cidofovir.148 Cidofovir has FDA approval “but not to combat adverse smallpox vaccine events.”149
Even if some of the risk can be contained, there is an ethical question of whether there is enough beneﬁt
involved in the trial to justify exposing healthy children to the risk. Vaccinated children will only beneﬁt
in the event of a bioterrorist attack.150 There are no current cases of smallpox. Many critics, such as the
American Academy of Pediatrics, believe that children should not receive the vaccine prior to an outbreak of
smallpox.151 If an outbreak does occur, experts say the vaccine can be administered three to four days after
exposure to the virus and still be eﬀective.152 On the other hand, those in favor of the trial believe that not
testing the vaccine on children is unethical. If an outbreak occurred without prior testing, they argue, the
government would be letting “millions of children be part of an emergency experiment.”153 Arguably, this
would be worse than testing a selected number of children now.
Another criticism focuses on the vulnerability of children and the possibility of misinformed parents. The
Alliance for Human Protection has criticized the CDC’s consent form.154 The organization argued that the
form misrepresents the fact that children are not currently at any particular risk of smallpox.155 Addition-
ally, critics argue that parents may be improperly inﬂuenced. The form talks about a $120 reimbursement
and a $40 gift certiﬁcate for children before the form mentions risks.156 Many commentators agree that
148See Susan J. Landers, American Medical News, Prudent to Test Smallpox Vaccine in Kids? (Dec. 2, 2002), available at
http://www.ama-assn.org/sci-pubs/amnews/pick 02/hlsc1202.htm (last visited Feb. 28, 2002).
149Id.
150See FoxNews.com, FDA Mulls When Smallpox Vaccine Study Should Begin for Children (Nov. 1, 2002), at
http://www.foxnews.com/story/0,2933,68722,00.html.
151See American Academy of Pediatrics, Children Should Not Be Given Smallpox Vaccine (Jan. 30, 2003), available
at http://www.aap.org/advocacy/washing/smallpox vaccine.htm (last visited Feb. 22, 2003).
152See Vera Sharav, Alliance for Human Research Protection, Comments re: Proposed Smallpox Vaccine Trial
to Test the Safety of Dryvax Administration to Children 2 to 5 Years of Age, FDA Docket Number 02N-0466, at 2,
available at http:www.fda.gov/ohrms/dockets/dailys/02/Dec02/120302/02N-0466-EC-450.htm (last visited Feb. 22, 2003).
153See American Academy of Pediatrics, Children Should Not Be Given Smallpox Vaccine (Jan. 30, 2003), available
at http://www.aap.org/advocacy/washing/smallpox vaccine.htm (last visited Feb. 22, 2003).
154See Vera Sharav, Alliance for Human Research Protection, Comments re: Proposed Smallpox Vaccine Trial
to Test the Safety of Dryvax Administration to Children 2 to 5 Years of Age, FDA Docket Number 02N-0466, at 6,
available at http:www.fda.gov/ohrms/dockets/dailys/02/Dec02/120302/02N-0466-EC-450.htm (last visited Feb. 22, 2003).
155See id.
156See id.
23fully explaining risks to parents is crucial.157 Some experts have suggested that FDA limit inoculations to
children of adults enrolled in vaccine studies, “because those parents may better understand the risks.”158
Better informed parents, however, does not seem to justify exposing helpless children to a potentially life
threatening disease.
FDA accepted comments regarding the trial until Dec. 2, 2002.159 Final determination on whether to proceed
with the trial was left with Secretary of the Department of Health and Human Services Tommy Thompson
and FDA Commissioner Mark McClellan, MD, PhD.160 On January 28, 2003, HHS placed a declaration
of smallpox countermeasures in the Federal Register.161 The declaration approves the use of Dryvax as a
countermeasure but limits its administration to certain health care workers, members of smallpox response
teams, public safety personnel, and personnel associated with certain U.S. Government facilities abroad.162
The declaration makes no mention of children or the proposed trial. It is likely that HHS and FDA have
decided to halt the trial.
The smallpox situation is particularly telling, because it tests the FDA’s regulations at its fringes. Section
50.54 only applies to the most questionable trials. Even then, the regulations state that the IRB must ﬁnd
and document that the investigation will help further understand, prevent, or alleviate a serious problem
aﬀecting the health or welfare of children.163 Because the threat of an outbreak of smallpox is speculative,
it does not seem to qualify as a “serious health problem aﬀecting the health or welfare of children.”164
Additionally, Section 50.54 requires the involvement of various experts and the involvement of the public.
157See FoxNews.com, FDA Mulls When Smallpox Vaccine Study Should Begin for Children (Nov. 1, 2002), at
http://www.foxnews.com/story/0,2933,68722,00.html.
158Id.
159Solicitation of Public Review and Comment On Research Protocol: A Multicenter, Randomized Dose Response Study of
the Safety, Clinical and Immune Response of Dryvax Administered to Children 2 to 5 Years of Age, 67 Fed. Reg. 211,66403
(Oct. 31, 2002).
160See Susan J. Landers, American Medical News, Prudent to Test Smallpox Vaccine in Kids? (Dec. 2, 2002), available at
http://www.ama-assn.org/sci-pubs/amnews/pick 02/hlsc1202.htm (last visited Feb. 28, 2002).
161Declaration Regarding Administration of Smallpox Countermeasures, 68 Fed. Reg. 18,4212 (Jan. 28, 2003).
162See id. at 4212-13.
163See 21 C.F.R. § 50.54 (2002).
164Id.
24Because FDA has not issued any formal ruling on whether the trial will proceed, it seems as if, in this case,
public comment and expert opinion were persuasive. Thus, one could conclude that FDA’s regulations do
work and do provide proper mechanisms for ensuring ethical standards and judgments. On the other hand,
if FDA does decide to proceed with the trial, the ethical impact of the regulations may be suspect.
Finally, for research not at the fringes, HHS’s announcement of its intent to fund testing of twelve commonly
prescribed drugs in children during ﬁscal year 2003 and 2004 reinforces FDA’s policy of encouraging pediatric
drug testing.165 For now, it seems as if FDA’s policies will stand.
V. Conclusion
FDA’s response to debates over pediatric drug testing reveals the competing duties of FDA to protect the
public but also to promote research. How risk adverse FDA will be in a given situation will depend upon its
analysis of the risk/beneﬁt calculus. FDA’s interim rule seems to provide a workable framework for assessing
diﬀerent ratios of risk and beneﬁt and seems to provide adequate opportunity for outside validation in the
most controversial situations. Although it has enormous power, FDA does remain accountable to the public
and to HHS, and its response to pediatric drug testing is an illustrative example of how FDA balances its
competing roles.
165See Department of Health and Human Services, HHS Identifies Drugs for Pediatric Testing and Announces
FY 2003 and FY 2004 Funding (2003), available at http://www.hhs.gov/news/press/2003pres/20030121.html (last visited
Feb. 22, 2003).
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